Literature DB >> 12029019

Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood.

Frank Streit1, Victor William Armstrong, Michael Oellerich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12029019

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  18 in total

1.  Correlation of tissue drug concentrations with in vivo magnetic resonance images of polymer drug depot around arteriovenous graft.

Authors:  Shawn C Owen; Huan Li; William G Sanders; Alfred K Cheung; Christi M Terry
Journal:  J Control Release       Date:  2010-05-08       Impact factor: 9.776

Review 2.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

Review 3.  A human proteome detection and quantitation project.

Authors:  N Leigh Anderson; Norman G Anderson; Terry W Pearson; Christoph H Borchers; Amanda G Paulovich; Scott D Patterson; Michael Gillette; Ruedi Aebersold; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2009-01-07       Impact factor: 5.911

4.  Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.

Authors:  David Guillén; Federico Cofán; Emilio Ros; Olga Millán; Montse Cofán; Mercè Brunet
Journal:  Mol Diagn Ther       Date:  2010-12-01       Impact factor: 4.074

5.  Sialic acid-focused quantitative mouse serum glycoproteomics by multiple reaction monitoring assay.

Authors:  Masaki Kurogochi; Takahiko Matsushista; Maho Amano; Jun-ichi Furukawa; Yasuro Shinohara; Masato Aoshima; Shin-Ichiro Nishimura
Journal:  Mol Cell Proteomics       Date:  2010-06-22       Impact factor: 5.911

6.  Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.

Authors:  Shirish M Gadgeel; Danika L Lew; Timothy W Synold; Patricia LoRusso; Vincent Chung; Scott D Christensen; David C Smith; Laura Kingsbury; Antje Hoering; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2013-09-22       Impact factor: 3.333

7.  Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay.

Authors:  Pierre Wallemacq; Gregory T Maine; Keith Berg; Thomas Rosiere; Pierre Marquet; Giuseppe Aimo; Giulio Mengozzi; Julianna Young; Kurt Wonigeit; Robert Kretschmer; Bendicht Wermuth; Rainer W Schmid
Journal:  Ther Drug Monit       Date:  2010-04       Impact factor: 3.681

Review 8.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  A rapid HPLC-MS/MS method for the simultaneous quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human blood samples.

Authors:  Christoph Seger; Karin Tentschert; Wolfgang Stöggl; Andrea Griesmacher; Steven L Ramsay
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

10.  A new approach for the determination of immunosuppressive drugs using HPLC-MS/MS and Cs+ adducts.

Authors:  Patricia Kaiser; Theodorus Akerboom; William Graham Wood; Hans Reinauer
Journal:  Ger Med Sci       Date:  2006-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.